Existing drugs have limited efficacy against the rising threat of drug-resistant TB, have
significant side effects, and must be given in combinations of four to six drugs for at least 6 …

The expectation that genomics would result in new therapeutic interventions for infectious
diseases remains unfulfilled. In the post‐genomic era, the decade immediately following the …

ABSTRACT MmpL3, a resistance-nodulation-division (RND) superfamily transporter, has
been implicated in the formation of the outer membrane of Mycobacterium tuberculosis; …

Background Nearly two decades after completion of the genome sequence of
Mycobacterium tuberculosis (MTB), and with the advent of next generation sequencing …

In recent years, whole-cell-based screens for novel small molecule inhibitors active against
Mycobacterium tuberculosis in culture followed by the whole-genome sequencing of …

Phenotypic screening of a quinoxaline library against replicating Mycobacterium
tuberculosis led to the identification of lead compound Ty38c (3-((4-methoxybenzyl) amino) …

Benzothiazinones (BTZ) are a new class of drug candidates to combat tuberculosis that
inhibit decaprenyl-phosphoribose epimerase (DprE1), an essential enzyme involved in …

Indole, an aza-heterocyclic scaffold, has been found one of the most privileged scaffolds in
heterocyclic chemistry and drug discovery. Efforts have been made to provide the complete …

Most of the newly discovered compounds showing promise for the treatment of TB, notably
multidrug-resistant TB, inhibit aspects of Mycobacterium tuberculosis cell envelope …

TB is an infectious disease that is far from being eradicated and controlled. The treatment for
TB is associated with noncompliance to therapy because it consists of a long-term treatment …